---
title: "Silexion Therapeutics 报告了积极的临床前数据，表明在系统给药后，SIL204 能够到达并在主要胰腺癌转移部位发挥作用"
description: "新的积极的临床前数据表明，在临床相关剂量下，药物成功分布到肝脏、腹膜和肺部，并且肿瘤负担显著减少"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/256914425.md"
published_at: "2025-09-11T11:38:39.000Z"
---

# Silexion Therapeutics 报告了积极的临床前数据，表明在系统给药后，SIL204 能够到达并在主要胰腺癌转移部位发挥作用

> 新的积极的临床前数据表明，在临床相关剂量下，药物成功分布到肝脏、腹膜和肺部，并且肿瘤负担显著减少

New Positive Preclinical Data Shows Succesful Drug Distribution to Liver, Peritoneum, and Lung with Measurable Reductions in Tumor Burden at Clinically Relevant Doses ...

### Related Stocks

- [SLXN.US - Silexion Therapeutics](https://longbridge.com/zh-CN/quote/SLXN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Silexion Therapeutics Publishes 2025 Shareholder Letter Highlighting Major Achievements | Silexion Therapeutics Corp. has published a shareholder letter from CEO Ilan Hadar, highlighting major achievements in 2 | [Link](https://longbridge.com/zh-CN/news/271656749.md) |
| Silexion Reports Positive Preclinical Data Demonstrating SIL204's Reach | Sept 11 (Reuters) - Silexion Therapeutics Corp:SILEXION THERAPEUTICS REPORTS POSITIVE PRECLINICAL DATA DEMONSTRATING SIL | [Link](https://longbridge.com/zh-CN/news/256907389.md) |
| Forget AI stocks: This pharma giant is using AI to dominate drug discovery | And there's more than one way to monetize this technology. | [Link](https://longbridge.com/zh-CN/news/276017486.md) |
| Cause of death for Catherine O'Hara identified | Catherine O'Hara's cause of death has been identified as pulmonary embolism, with rectal cancer as an underlying factor. | [Link](https://longbridge.com/zh-CN/news/275452756.md) |
| 11:07 ETSensing Local Fibers in Pancreatic Tumors, Cancer Cells 'Choose' to Either Grow or Tolerate Treatment | A study led by NYU Langone Health reveals that pancreatic cancer cells can switch between growth and survival modes base | [Link](https://longbridge.com/zh-CN/news/276067906.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。